Skip to content
  • CONTACT US
  • CAREERS
  • Share
Allogene Logo
  • ABOUT US
    • AT A GLANCE
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • SCIENTIFIC ADVISORS
    • PARTNERS
  • AlloCAR T™
    • HISTORY OF CAR T
    • NEXT REVOLUTION IN CELL THERAPY
    • PLATFORM FOR TOMORROW
    • ON-DEMAND AVAILABILITY
  • PIPELINE
    • AlloCAR T™ PIPELINE
    • DATABRIEF
    • CLINICAL TRIALS
    • EXPANDED ACCESS
    • SCIENTIFIC PUBLICATIONS
  • OUR CULTURE
    • ESG REPORT
    • WE ARE ONE ALLOGENE
    • REVOLUTIONIZING CELL THERAPY
    • DIVERSITY, EQUITY, INCLUSION AND BELONGING
    • JOIN THE ALLOGENE COMMUNITY
  • NEWS CENTER
    • PRESS RELEASES
    • EVENTS
    • PERSPECTIVES
    • OUR TWEETS
    • COMMUNITY GUIDELINES
  • INVESTORS
    • IR OVERVIEW
    • NEWS & EVENTS
      • PRESS RELEASES
      • EVENTS
      • PRESENTATIONS
    • STOCK INFORMATION
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
      • INVESTMENT CALCULATOR
    • CORPORATE GOVERNANCE
      • DOCUMENTS & CHARTERS
      • ESG REPORT
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIALS & FILINGS
      • SEC FILINGS
    • RESOURCES
      • INVESTOR FAQs
      • EMAIL ALERTS
      • IR INQUIRY
  • ABOUT US
    • AT A GLANCE
    • MANAGEMENT TEAM
    • BOARD OF DIRECTORS
    • SCIENTIFIC ADVISORS
    • PARTNERS
  • AlloCAR T™
    • HISTORY OF CAR T
    • NEXT REVOLUTION IN CELL THERAPY
    • PLATFORM FOR TOMORROW
    • ON-DEMAND AVAILABILITY
  • PIPELINE
    • AlloCAR T™ PIPELINE
    • DATABRIEF
    • CLINICAL TRIALS
    • EXPANDED ACCESS
    • SCIENTIFIC PUBLICATIONS
  • OUR CULTURE
    • ESG REPORT
    • WE ARE ONE ALLOGENE
    • REVOLUTIONIZING CELL THERAPY
    • DIVERSITY, EQUITY, INCLUSION AND BELONGING
    • JOIN THE ALLOGENE COMMUNITY
  • NEWS CENTER
    • PRESS RELEASES
    • EVENTS
    • PERSPECTIVES
    • OUR TWEETS
    • COMMUNITY GUIDELINES
  • INVESTORS
    • IR OVERVIEW
    • NEWS & EVENTS
      • PRESS RELEASES
      • EVENTS
      • PRESENTATIONS
    • STOCK INFORMATION
      • STOCK QUOTE & CHART
      • HISTORIC PRICE LOOKUP
      • INVESTMENT CALCULATOR
    • CORPORATE GOVERNANCE
      • DOCUMENTS & CHARTERS
      • ESG REPORT
      • BOARD OF DIRECTORS
      • MANAGEMENT
      • COMMITTEE COMPOSITION
    • FINANCIALS & FILINGS
      • SEC FILINGS
    • RESOURCES
      • INVESTOR FAQs
      • EMAIL ALERTS
      • IR INQUIRY

Allogene Therapeutics Appoints Earl Douglas as General Counsel

  • Post author:andrewkaretas
  • Post published:August 14, 2023
  • Post category:Latest News

SOUTH SAN FRANCISCO, Calif. , Aug. 14, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products…

Continue ReadingAllogene Therapeutics Appoints Earl Douglas as General Counsel

4: Statement of changes in beneficial ownership of securities

  • Post author:andrewkaretas
  • Post published:August 9, 2023
  • Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading4: Statement of changes in beneficial ownership of securities

144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

  • Post author:andrewkaretas
  • Post published:August 7, 2023
  • Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

10-Q: Quarterly report which provides a continuing view of a company's financial position

  • Post author:andrewkaretas
  • Post published:August 2, 2023
  • Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading10-Q: Quarterly report which provides a continuing view of a company's financial position

8-K: Report of unscheduled material events or corporate event

  • Post author:andrewkaretas
  • Post published:August 2, 2023
  • Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading8-K: Report of unscheduled material events or corporate event

Allogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

  • Post author:andrewkaretas
  • Post published:August 2, 2023
  • Post category:Latest News

Presented Long-Term Data for an Allogeneic CD19 CAR T Product Candidate in Relapsed/Refractory Large B Cell Lymphoma (LBCL) at the American Society of Clinical Oncology (ASCO) Annual Meeting and International…

Continue ReadingAllogene Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

August 2, 2023 5:00 PM EDT : Allogene Therapeutics Second Quarter 2023 Conference Call

  • Post author:andrewkaretas
  • Post published:July 26, 2023
  • Post category:Events

Continue ReadingAugust 2, 2023 5:00 PM EDT : Allogene Therapeutics Second Quarter 2023 Conference Call

Allogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

  • Post author:andrewkaretas
  • Post published:July 26, 2023
  • Post category:Latest News

Conference Call and Webcast Scheduled for 2:00 PM PT / 5:00 PM ET SOUTH SAN FRANCISCO, Calif. , July 26, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a…

Continue ReadingAllogene Therapeutics to Report Second Quarter 2023 Financial Results on August 2, 2023

SC 13G: A statement of beneficial ownership of common stock by certain persons

  • Post author:andrewkaretas
  • Post published:July 10, 2023
  • Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue ReadingSC 13G: A statement of beneficial ownership of common stock by certain persons

144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing

  • Post author:andrewkaretas
  • Post published:June 29, 2023
  • Post category:SEC Filings

Allogene Therapeutics, Inc.

Continue Reading144: Filed by “insiders” prior intended sale of restricted stock. Non-EDGAR filing
  • Go to the previous page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 13
  • Go to the next page

Recent Posts

  • Allogene Therapeutics Announces Three Poster Presentations from its Next Generation AlloCAR T™ Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
  • September 26, 2023 11:00 AM EDT : Jefferies Cell & Genetic Medicine Summit
  • September 26, 2023 – September 27, 2023 : Jefferies Cell & Genetic Medicine Summit
  • September 12, 2023 3:45 PM EDT : Baird 2023 Global Healthcare Conference
  • Allogene Therapeutics Announces Participation in September Investor Conference

Recent Comments

No comments to show.
Allogene

CONNECT

210 E. Grand Avenue
South San Francisco, CA 94080

View Map / Contact Us

LinkedIn
Twitter
  • ABOUT US
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
  • AlloCAR T™
    • History of CAR T
    • Next Revolution in Cell Therapy
    • Platform for Tomorrow
    • On-Demand Availability
  • PIPELINE
    • AlloCAR T™ Pipeline
    • DATABRIEF
    • Clinical Trials
    • Expanded Access
    • Scientific Publications
  • OUR CULTURE
    • ESG Report
    • We Are One Allogene
    • Revolutionizing Cell Therapy
    • Diversity, Equity, Inclusion and Belonging
    • Join the Allogene Community
  • NEWS CENTER
    • Press Releases
    • Events
    • Perspectives
    • Our Tweets
    • Community Guidelines
  • INVESTORS
    • Press Releases
    • Events
    • Presentations
    • Stock Information
    • Historic Price Lookup
    • Investment Calculator
    • Corporate Governance
    • Committee Composition
    • SEC Filings
    • Resources/FAQs
    • Email Alerts
    • Investor Contacts
Facebook
Twitter
LinkedIn
E-Mail
Tumblr
Reddit
WhatsApp
Telegram
Allogene

CONNECT

210 E. Grand Avenue
South San Francisco, CA 94080

View Map / Contact Us

LinkedIn
Twitter
  • ABOUT US
    • At a Glance
    • Management Team
    • Board of Directors
    • Scientific Advisors
    • Partners
  • AlloCAR T™
    • History of CAR T
    • Next Revolution in Cell Therapy
    • Platform for Tomorrow
    • On-Demand Availability
  • PIPELINE
    • AlloCAR T™ Pipeline
    • DATABRIEF
    • Clinical Trials
    • Expanded Access
    • Scientific Publications
  • OUR CULTURE
    • ESG Report
    • We Are One Allogene
    • Revolutionizing Cell Therapy
    • Diversity, Equity, Inclusion and Belonging
    • Join the Allogene Community
  • NEWS CENTER
    • Press Releases
    • Events
    • Perspectives
    • Our Tweets
    • Community Guidelines
  • INVESTORS
    • Press Releases
    • Events
    • Presentations
    • Stock Information
    • Historic Price Lookup
    • Investment Calculator
    • Corporate Governance
    • Committee Composition
    • SEC Filings
    • Resources/FAQs
    • Email Alerts
    • Investor Contacts

©2022 ALLOGENE THERAPEUTICS

TERMS OF USE

COOKIE SETTINGS

PRIVACY NOTICE

©2022 ALLOGENE THERAPEUTICS

TERMS OF USE

COOKIE SETTINGS

PRIVACY NOTICE